PhaseII safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC
Not Applicable
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000015094
- Lead Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 17
Inclusion Criteria
Not provided
Exclusion Criteria
1) known interstitial fibrosis or interstitial lung disease 2) Evidence of active malignancy 3) Brain metastasis with disordered consciousness 4) Uncontrolled Grade >/=3 SVC syndrome, pericardial effusion, pleural effusion, ascites 6) Active infectious disease 7) Concurrent radiotherapy including lung field
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective Response Rate
- Secondary Outcome Measures
Name Time Method PS improvement rate Safety Progression Free Survival Overall Survival